MEETING AGENDAS AND MINUTES INFORMATION: See the Utah Public Notice Website. Search Categories: Government: State Entity: Department of Health Body: Cannabinoid Product Board. MEETING RECORDINGS: See the CPB YouTube Page.
Cannabinoid Product Board Information
The Cannabinoid Product Board (CPB) is the result of the Cannabinoid Research Act, (H.B. 130) that was passed and was signed into law during the 2017 Utah General Legislative Session. During the 2018 Utah General Legislative Session, amendments (H.B. 25) were made to Cannabinoid Research Act as follows:
- The composition of the CPB was modified from three board members being members of the Controlled Substance Advisory Committee to one; and
- The duties of the CPB were broadened to include review of research regarding “expanded cannabinoid products” which includes cannabinoid products with significant tetrahydrocannabinol (THC) content.
The Cannabinoid Research Act directs the Utah Department of Health (UDOH) to form and facilitate the CPB. As stated in the legislation, the purpose of the CPB is to review available research related to the human use of cannabinoid products. Specifically, the CPB evaluates the safety and efficacy of cannabinoid products and expanded cannabinoid products in terms of: 1) medical conditions that respond to cannabinoid products; 2) dosage amounts and their medical forms; and 3) interactions between cannabinoid products, expanded cannabinoid products, and other treatments. The CPB may only review research that has been approved by an Institutional Review Board, or approved/conducted by the federal government.
From this research, the CPB is directed to develop prescribing guidelines that may potentially be used by qualified medical providers recommending cannabinoid products to their patients. The CPB is directed to report the findings of their evaluation in writing to the Health and Human Services Interim Committee before November 1st of each year.
BOARD MEMBERS
Perry G. Fine, M.D. (Board Chair)
Professor of Anesthesiology, Division of Pain Medicine, School of Medicine, University of Utah
Misty D. Smith, Ph.D.
Research Assistant Professor, Department of Pharmacology & Toxicology, College of Pharmacy
Ed Redd, M.D.
Internal Medicine Physician
Past member of the Utah State Legislature
Katherine Carlson, M.D., M.S.
Addiction Psychiatrist
Medical Director, Project Reality Substance Abuse Treatment and Prevention Services
Lauren J. Heath, Pharm.D., M.S., B.C.A.C.P.
Assistant Professor (Clinical), Department of Pharmacotherapy, University of Utah College of Pharmacy
Brian Keith Zehnder, M.D.
Medical Director, Exodus Healthcare Network, PLLC,
Past member of the Utah State Legislature
CPB Research By Diagnosis
The information provided in the following documents is intended to help patients in Utah and Utah health care professionals to make well-informed decisions to improve the quality of health care outcomes in patients using medical cannabis through the Utah Medical Cannabis Program. The use of medical cannabis is at one’s own risk and the use of medical cannabis is not considered a first-line therapy for most medical conditions. The Utah Department of Health and the Center for Medical Cannabis highly advise that patients consult with their physician on using medical cannabis as a medical treatment. Documents provided on this website discuss warnings and risks related to the use of cannabis and as such, patrons using these documents are advised to use documents listed here as informational and educational only.
We advise that patrons who are minors using medical cannabis also understand and refer to official policy statements and positions posted by the American Academy of Pediatrics (2004 Policy and an updated 2015 Policy).
|
Condition/Subject |
Approved Condition |
CPB Discussion Notes |
CPB Guidance Document |
Presentations & Relevant Documents |
|
General Use |
N/A |
|
|
|
|
Chronic Pain |
Yes |
A presentation was given by Dr. Perry Fine, M.D., during the Aug 2020 meeting. Notes from the CPB’s discussion can be found in the 2020 Meeting Minutes document and also in the 2020 Annual Report. |
|
|
|
ALS |
Yes |
|
|
|
|
Alzheimer’s |
Yes |
|
|
|
|
HIV/AIDS |
Yes |
|
|
|
|
Multiple Sclerosis |
Yes |
A presentation was given by Dr. Joel Ehrenkranz, M.D., during the June 2020 CPB meeting. Notes from the CPB’s discussion can be found in the 2020 Meeting Minutes document and also in the 2020 Annual Report. |
|
|
|
Autism |
Yes |
|
|
|
|
Cancer |
Yes |
|
|
|
|
Cancer and Chemotherapy-Induced Nausea and Vomiting |
Yes |
|
|
|
|
Crohn’s Disease and Ulcerative Colitis |
Yes |
|
|
|
|
Epilepsy |
Yes |
|
|
|
|
PTSD |
Yes |
A presentation by Dr. Katherine Carlson was given during the December 2020 meeting. Notes from the CPB’s discussion can be found in the 2021 Meeting Minutes document and also in the 2021 Annual Report. |
Cannabis and Cannabinoids for Post Traumatic Stress Disorder |
|
|
Anxiety |
No |
A presentation by Dr. Michael Crookston was given during the December 2020 meeting. Notes from the CPB’s discussion can be found in the 2021 Meeting Minutes document and also in the 2021 Annual Report. |
N/A |
|
|
Opioid Use/Opioid Use Disorder |
No |
A presentation by Dr. Adam Gordon, MD MPH FACP DFASAM, was given during the January 2021 CPB meeting. Notes from the CPB’s discussion can be found in the 2021 Meeting Minutes document and also in the 2021 Annual Report. |
N/A |
OUD Document (coming soon) |
|
Suppository Administration of Cannabis Products |
No |
A presentation by Karen S. Wilcox, PhD |
